Key result
The Micra Transcatheter Pacing System had a 24-month system revision rate of 1.4%, which was 75% lower than the 5.3% rate in patients with transvenous pacemakers.
Why the study?
Does the Micra Transcatheter Pacing System reduce system revision rates compared to transvenous pacemakers?
Cohort (n=3,656)
Does the Micra Transcatheter Pacing System reduce system revision rates compared to transvenous pacemakers?
The Micra leadless pacemaker is associated with a significantly lower 24-month system revision rate compared to traditional transvenous pacemakers.
Answers are grounded in this paper and cite their sources.
May favor leadless pacing to reduce revisions; observational data leaves open need for randomized confirmation.
BACKGROUND: Early experience with leadless pacemakers has shown a low rate of complications. However, little is known about system revision in patients with these devices. OBJECTIVE: The purpose of this study was to describe the system revision experience with the Micra Transcatheter Pacing System (TPS). METHODS: Patients with implants from the Pre-market Micra Transcatheter Pacing Study and the Micra Transcatheter Pacing System Continued Access Study (N = 989) were analyzed and compared with 2667 patients with transvenous pacemakers (TVPs). Revisions included TPS retrieval/explant, repositioning, replacement, or electrical deactivation (with or without prior attempt at retrieval, generally followed by TVP implant) for any reason. Kaplan-Meier revision rates were calculated to account for varying follow-up duration and were compared using a Fine-Gray competing risk model. RESULTS: The actuarial rate for revision at 24 months postimplant was 1.4% for the TPS group (11 revisions in 10 patients), 75% (95% confidence interval 53%-87%; P < .001) lower than the 5.3% for the TVP group (123 revisions in 117 patients). TPS revisions occurred 5-430 days postimplant for elevated pacing thresholds, need for alternate therapy, pacemaker syndrome, and prosthetic valve endocarditis; none were due to device dislodgment or device-related infection. TPS was disabled and left in situ in 7 cases, 3 were retrieved percutaneously (range 9-406 days postimplant), and 1 was surgically removed during aortic valve surgery. CONCLUSION: The overall system revision rate for patients with TPS at 24 months was 1.4%, 75% lower than that for patients with TVPs. TPS was disabled and left in situ in 64% of revisions, and percutaneous retrieval was successful as late as 14 months postimplant.
No takes yet. Share an insight, caveat, or question.
Grubman et al. (2017) conducted a cohort in Pacemaker indication (n=3,656). Micra Transcatheter Pacing System (TPS) vs. Transvenous pacemakers (TVPs) was evaluated on System revision (retrieval/explant, repositioning, replacement, or electrical deactivation) (75% lower, 95% CI 53%-87%, p=<.001). The Micra Transcatheter Pacing System had a 24-month system revision rate of 1.4%, which was 75% lower than the 5.3% rate in patients with transvenous pacemakers.
Synapse has enriched 10 related papers. Consider them for comparative context: